The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
|Videos|July 6, 2020
Toxicity Profile of CAR T-Cell Therapy Appears Safe in Follicular and Marginal Zone Lymphomas
Author(s)Caron Jacobson, MD
Caron Jacobson, MD, discusses the safety findings from the phase 2 ZUMA-5 tidal evaluating axicabtagene ciloleucel in patients with follicular lymphoma and marginal zone lymphoma.
Advertisement
Caron Jacobson, MD, medical director of the Immune Effector Cell Therapy Program and physician at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses the safety findings from the phase 2 ZUMA-5 tidal evaluating a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel; Yescarta), in patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL).
The safety profile was a little better in the FL cohort, so much so that it potentially raises the question of whether axi-cel could be administered in the outpatient setting, Jacobson says. About 23% of patients in the FL cohort had no cytokine release syndrome (CRS), and among those that did have CRS, the median time to onset was 4 days as opposed to 2 days in large cell lymphoma. Only 7% if patients in the FL cohort had high-grade CRS.
In terms of neurological toxicity in the FL cohort, 15% had high-grade events, which remains in line with what is expected with axi-cel in large cell lymphoma, Jacobson says.
The MZL cohort had a slightly higher incidence of CRS and higher-grade neurological toxicity that was more aligned with data for diffuse large B-cell lymphoma, according to Jacobson. The median time to onset of CRS in this cohort was about 4 days as well, so it was the same degree of toxicity with the FL cohort but later than we are used to seeing in large cell lymphoma.
Advertisement
Related to this article
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Anbal-cel demonstrated a 67.1% complete response rate in relapsed or refractory LBCL in the phase 1/2 CRC01-01 trial, evaluating dual PD-1 and TIGIT knockdown CAR T-cell therapy.
Patients with relapsed or refractory CTCL who responded to denileukin diftitox-cxdl experienced improvements in skin-related quality of life and overall well-being in Study 302.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
2
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
3
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
4
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
5